A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. by Taylor, Matthew H et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
4-7-2020 
A mutation-specific, single-arm, phase 2 study of dovitinib in 
patients with advanced malignancies. 
Matthew H Taylor 
Providence St. Joseph Health 




See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Oncology Commons 
Recommended Citation 
Taylor, Matthew H; Alva, Ajjai S; Larson, Timothy; Szpakowski, Sebastian; Purkaystha, Das; Amin, Alpesh; 
Karpiak, Linda; and Piha-Paul, Sarina A, "A mutation-specific, single-arm, phase 2 study of dovitinib in 
patients with advanced malignancies." (2020). Articles, Abstracts, and Reports. 3773. 
https://digitalcommons.psjhealth.org/publications/3773 
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has 
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. 
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org. 
Authors 
Matthew H Taylor, Ajjai S Alva, Timothy Larson, Sebastian Szpakowski, Das Purkaystha, Alpesh Amin, 
Linda Karpiak, and Sarina A Piha-Paul 
This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/3773 
Oncotarget1235www.oncotarget.com
www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 14), pp: 1235-1243
A mutation-specific, single-arm, phase 2 study of dovitinib in 
patients with advanced malignancies
Matthew H. Taylor1, Ajjai S. Alva2, Timothy Larson3, Sebastian Szpakowski4, Das 
Purkaystha5, Alpesh Amin5, Linda Karpiak5 and Sarina A. Piha-Paul6
1Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
2Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA
3USOR – Minnesota Oncology, Minneapolis, MN, USA
4Novartis Institutes for Biomedical Research, Cambridge, MA, USA
5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
6Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence to: Matthew H. Taylor, email: taylmatt@ohsu.edu
Keywords: advanced malignancies; basket trial; dovitinib; histology-agnostic; mutation-specific
Received: November 11, 2019 Accepted: March 03, 2020 Published: April 07, 2020
Copyright: Taylor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Background: Receptor tyrosine kinases (RTKs) play key roles in tumorigenesis. 
The multi-RTK inhibitor dovitinib has demonstrated promising antitumor activity in 
multiple cancers.
Patients and Methods: In this phase 2, open-label, single-arm study, patients 
with advanced malignancies with RTK-pathway genetic aberrations whose disease 
progressed on/following standard treatment received dovitinib (500 mg/day; 5-days-
on/2-days-off). The primary endpoint was clinical benefit rate (CBR; complete 
response, partial response [PR], or stable disease [SD] for ≥ 16 weeks).
Results: Of 80 patients enrolled, common tumors included gastrointestinal stromal 
tumors (GIST; 20.0%), colorectal cancer (CRC; 18.8%), and ovarian cancer (10.0%). 
Patients were heavily pretreated (median prior lines = 4; 67.5% had ≥ 3 prior lines). 
Genetic aberrations included cKIT (28.8%), FGFR3 (15.0%), and RET (15.0%). The 
CBR was 13.8%; one PR (GIST) and 10 SD (adenoid cystic [n = 3]; ovarian [n = 3]; 
GIST [n = 2]; CRC [n = 1]; gastroesophageal junction [n = 1]). The most common 
treatment-related adverse events were fatigue, diarrhea, nausea, and vomiting.
Conclusions: In this heterogeneous patient population, the safety profile was 
acceptable for dovitinib therapy. A subset of patients with RTK pathway-activated 
tumors experienced clinical benefit. However, the primary endpoint was not met, 
suggesting further refinement of predictive biomarkers is required.
INTRODUCTION
Receptor tyrosine kinases (RTKs), including 
vascular endothelial growth factor receptor (VEGFR), 
fibroblast growth factor receptor (FGFR), platelet-derived 
growth factor receptor (PDGFR), and the proto-oncogene 
cKIT play multiple roles in tumor growth, development, 
and survival [1]. Mutations in RTKs that result in aberrant 
signaling have been linked to tumorigenesis [2]. The 
prevalence and role of RTK mutations in human cancers 
has been the subject of a number of clinical studies. 
Activating mutations in cKIT and PDGFRα are common 
in gastrointestinal stromal tumors and are thought to 
play crucial roles in tumor initiation [3, 4]. Aberrations 
in FGFRs have been observed across multiple tumor 
types, most commonly in urothelial, breast, endometrial, 
squamous lung cancer, and ovarian cancers [1, 5].
Dovitinib (TKI258) is a small molecule multi-kinase 
inhibitor that targets a number of RTKs, including FGFR, 
VEGFR, PDGFR, colony stimulating factor 1 receptor 
(CSF-1R), cKIT, RET, tropomyosin receptor kinase A 
(TrkA), and fms-related tyrosine kinase 3 (FLT3) [6]. 
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This broad range of targets is the mechanistic basis for 
the antiproliferative and antiangiogenic effects of dovitinib 
observed in preclinical studies [6–8]. In the clinic, 
dovitinib has demonstrated promising activity in a number 
of cancers, including as a single agent in gastrointestinal 
stromal tumors [9] and in combination with fulvestrant in 
advanced breast cancer [10].
In this trial (NCT01831726), dovitinib was 
investigated as part of the Novartis Signature Program 
(8 phase 2, signal-finding, basket trials of different 
single-agent targeted therapies in a genetic alteration-
specific manner) [11]. The purpose of this tumor 
histology-agnostic study was to determine whether 
dovitinib treatment demonstrated sufficient efficacy 




Between August 15, 2013 and December 17, 2015, 
80 patients with advanced malignancies were enrolled and 
received at least one dose of dovitinib. Baseline patient 
characteristics are shown in Table 1. The median age was 
60 years (range: 29–80) and the patient population was 
heavily pretreated with a median number of 4 prior lines 
of anticancer therapy (range: 0–14); 67.5% of patients 
had received at least 3 prior lines. Gastrointestinal stromal 
tumor (20.0%), colorectal cancer (18.8%), and ovarian 
cancer (10.0%) were the most common solid malignancies; 
no patients with hematologic malignancies were enrolled. 
Tumor type cohorts of at least 4 patients were formed 
in the following malignancies: gastrointestinal stromal 
tumor (n = 16), colorectal cancer (n = 15), ovarian 
cancer (n = 8), adenoid cystic carcinoma (n = 7), head 
and neck squamous cell carcinoma (n = 5), non-small cell 
lung cancer adenocarcinoma (n = 4), and thymus cancer 
(n = 4). The most common (in ≥ 15.0% of patients) genetic 
aberrations that were required for patient enrollment were 
cKIT (28.8%), FGFR3 (15.0%), and RET (15.0%).
At final data cut-off (February 10, 2016) all patients 
had discontinued treatment, most commonly due to disease 
progression (61.3%; Supplementary Figure 1). The median 
duration of dovitinib treatment was 1.78 months (range: 0.1–
16.7) with the majority of patients treated for a maximum 
of 2 months (61.3%). The median duration of follow-up 
was 29.9 months. Dovitinib dose was reduced in 39 patients 
(48.8%) with adverse events the most common reason for 
dose reduction in 37 patients (46.3%). The median relative 
dose intensity for dovitinib was 100% (range: 40–100).
Safety
Of all patients who received at least one dose 
of dovitinib and had at least one post-baseline safety 
assessment, 74 patients (92.5%) experienced a treatment-
emergent adverse event, suspected to be related to study 
drug (Table 2). The most common treatment-emergent–
related adverse events of any grade in ≥ 30% of patients 
were fatigue (60.0%) and the gastrointestinal disorders 
diarrhea (55.0%), nausea (53.8%), and vomiting (41.3%). 
Grade 3/4 treatment-emergent suspected-related adverse 
events were experienced by 45 patients (56.3%); fatigue 
was the most common in 14 patients (17.5%). Decreased 
platelet count, hypertriglyceridemia, and increased gamma-
glutamyltransferase were the only Grade 4 adverse events 
reported in more than 1 patient (2 patients [2.5%] each).
Treatment-emergent adverse events requiring dose 
adjustment or interruption, suspected to be related to 
study drug, were reported in 45 patients (56.3%); these 
were most commonly (in ≥ 5.0% of patients), fatigue 
(21.3%), gastrointestinal disorders including nausea 
(12.5%), diarrhea (11.3%) and vomiting (7.5%), and 
hypertension (5.0%). Adverse events were the cause of 
treatment discontinuation in 16 patients (20.0%). Nine 
patients (11.3%) died during the study or within 30 days 
of treatment discontinuation; of these, death was the 
cause of study discontinuation in seven patients (8.8%; 
Supplementary Figure 1). Patient deaths were due to 
disease progression (n = 5 [6.25%]) and serious adverse 
events (n = 4 [5.0%]). The serious adverse events leading 
to death were acute thrombotic cerebrovascular event, 
pulmonary embolism, acute respiratory failure, and cardiac 
arrest. The cases of acute thrombotic cerebrovascular 
event and pulmonary embolism were suspected to be 
related to study drug.
Efficacy
Clinical benefit was experienced by 11 patients 
(13.8%); 10 patients (12.5%) had stable disease for at 
least 16 weeks and 1 patient (1.3%) had a partial response 
lasting 116 days (Table 3). Stable disease was experienced 
by patients in the following tumor cohorts: adenoid cystic 
tumor (n = 3), ovarian tumor (n = 3), gastrointestinal 
stromal tumor (n = 2), and colorectal tumor (n = 1). 
Outside of the tumor cohorts, stable disease was also 
reported in an additional patient with a gastroesophageal 
junction tumor. The following tumor mutations were 
reported in patients with clinical benefit: cKIT (n = 1), 
CSF-1R (n = 1), PDGFRα (n = 2), PDGFRβ (n = 1), 
VEGFR1 (n = 1), VEGFR2 (n = 2), FLT3 (n = 1), FGFR2 
(n = 2), RET (n = 1), and TrkA (n = 1).
The patient with a partial response was a 49-year-old 
male with a gastrointestinal stromal tumor and metastatic 
sites in the lung, liver, and jejunum. The best percentage 
change from baseline in the size of target lesion was –38.6%. 
He had received 3 prior lines of therapy. Sequencing 
of a stomach tumor biopsy taken 46.1 months prior to 
study start per local analysis revealed presence of a cKIT 
mutation; posthoc central sequencing analysis highlighted 
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an additional mutation in VEGFR2. The patient had received 
the following therapies between the date of biopsy and first 
dose of dovitinib: imatinib, sunitinib, and regorafenib.
Median progression-free survival in all patients 
treated with dovitinib was 2.4 months (95% confidence 
interval [CI]: 1.8–3.7) with 60 (75.0%) events. The median 
overall survival was 13.5 months (95% CI: 5.9–14.7) with 
34 (42.5%) events. Of the 7 tumor cohorts that enrolled at 
least 4 patients (adenoid cystic, colorectal, gastrointestinal 
stromal, head and neck squamous cell carcinoma, lung non-
small cell adenocarcinoma, ovarian, and thymus), none 
passed the prespecified threshold of benefit according to 
Bayesian analysis and futility was declared (Figure 1).
Genomic profiling
The most common protocol-defined genetic 
aberration was in cKIT (28.8%; Table 4). Alterations in the 
following genes were also common (in ≥ 10% of patients): 
FGFR3 and RET (in 15.0% of patients each), and FGFR1 
and VEGFR2 (in 10.0% of patients each). The median 
time from the date of tumor biopsy used for sequencing to 
first dose of dovitinib was 18.8 months (range: <1–120). 
The tumor biopsy was obtained within 12 months prior to 
dovitinib treatment in 28 patients – genomic alterations are 
shown in Figure 2 with specific nucleotide substitutions 
detailed in Supplementary Table 2. Of these patients, 13 
had received no anticancer therapy from the time of tumor 
biopsy to the start of dovitinib therapy. The remaining 
15 patients had received at least one line of therapy after 
collection of the biopsy sample; 5 of these biopsy samples 
were collected at disease onset.
Response rates in those patients with recent biopsies 
(within 12 months of study treatment) included 1 patient 
who achieved stable disease, 17 patients with progressive 
disease, and 10 patients who were not evaluable for 
Table 1: Patient baseline characteristics
Characteristic Patients (N = 80)









ECOG PS, n (%)
0 38 (47.5)
1 42 (52.5)
Primary tumor type, n (%)
Gastrointestinal stromal tumor 16 (20.0)




NSCLC adenocarcinoma 4 (5.0)
Thymus 4 (5.0)
Other/unknowna 21 (26.3)






≥ 5 26 (32.5)
aOther tumors in fewer than 4 patients were: sarcoma (n = 3), central nervous system, lung non-small cell non-adenocarcinoma, neuroendocrine, pancreas, 
and small intestine (n = 2 each), and cervix, gall bladder, gall bladder ducts, gastroesophageal junction, and melanoma (n = 1 each). Primary tumor type was 
unknown in 3 patients. Abbreviations: ACC, adenoid cystic carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; HNSCC, head 
and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer.
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clinical benefit. The patient with stable disease and 
ovarian cancer was a 52-year-old female who had 
previously been treated with 6 lines of therapy including 
carboplatin, paclitaxel, cisplatin, carboplatin plus 
gemcitabine, insulin-like growth factor binding protein 
2-targeted therapy, cyclophosphamide, and letrozole. 
The best percentage change from baseline was –5.1%. 
Local sequencing analysis of a biopsy from the primary 
ovarian tumor collected 2.5 months prior to the study 
start, approximately 3 weeks before cessation of letrozole 
therapy, revealed the presence of RET and TrkA (NTRK1) 
protocol-defined mutations. The following aberrations in 
genes known to be implicated in tumor development were 
also present: CCNE1, MDM2, MITF, NFKBIA, PIK3CA 
amplifications, and short-variant mutations of BCORL1, 
CDK12, and TP53.
DISCUSSION
This signal-seeking study assessed the efficacy of 
dovitinib in patients with solid tumors possessing genetic 
aberrations in RTKs. The primary endpoint of the clinical 
benefit rate was not met, with an observed clinical benefit 
rate of 13.8% including 1 patient who experienced a partial 
response. Clinical benefit was assessed and compared to 
historical rates in tumor cohorts of gastrointestinal stromal 
tumor, colorectal cancer, ovarian cancer, adenoid cystic 
carcinoma, head and neck squamous cell carcinoma, 
non-small cell lung cancer adenocarcinoma, and thymus 
cancer. Although no tumor histology cohort met the 
prespecified threshold associated with success, it should 
be noted that the partial response was observed in the 
presence of cKIT and VEGFR2 mutations. Several patients 
experienced clinical benefit with tumor mutations in cKIT, 
CSF-1R, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, FLT3, 
FGFR2, RET, and TrkA.
Overall, the observed safety profile in this 
heterogenous patient population was acceptable for dovitinib 
treatment; the reported adverse events are consistent with 
the known safety profile of dovitinib monotherapy [17, 18]. 
No new safety signals emerged during this study. Adverse 
events thought to be related to dovitinib therapy were 
experienced by 92.5% of patients, the majority were Grade 
2 or 3 in severity. Fatigue and gastrointestinal disorders 
including diarrhea, nausea, vomiting, and decreased appetite 
were among the most commonly reported adverse events.
Table 2: Treatment-emergent adverse events suspected to be related to dovitinib in ≥ 10% of 
patients
Adverse event, n (%)
Patients (N = 80)
Grade 1 Grade 2 Grade 3/4 Any grade
Any adverse event 5 (6.3) 24 (30.0) 45 (56.3) 74 (92.5)
Fatigue 12 (15.0) 22 (27.5) 14 (17.5) 48 (60.0)
Diarrhea 24 (30.0) 14 (17.5) 6 (7.5) 44 (55.0)
Nausea 22 (27.5) 16 (20.0) 5 (6.3) 43 (53.8)
Vomiting 21 (26.3) 8 (10.0) 4 (5.0) 33 (41.3)
Hypertriglyceridemia 8 (10.0) 9 (11.3) 6 (7.5) 23 (28.8)
Decreased appetite 11 (13.8) 9 (11.3) 2 (2.5) 22 (27.5)
Increased blood AP 5 (6.3) 8 (10.0) 5 (6.3) 18 (22.5)
Increased AST 11 (13.8) 3 (3.8) 1 (1.3) 15 (18.8)
Asthenia 4 (5.0) 6 (7.5) 3 (3.8) 13 (16.3)
Dehydration 2 (2.5) 9 (11.3) 2 (2.5) 13 (16.3)
Decreased weight 6 (7.5) 6 (7.5) 0 12 (15.0)
Increased ALT 9 (11.3) 3 (3.8) 0 12 (15.0)
Increased GGT 3 (3.8) 4 (5.0) 5 (6.3) 12 (15.0)
Hypertension 4 (5.0) 2 (2.5) 4 (5.0) 10 (12.5)
Rash 7 (8.8) 3 (3.8) 0 10 (12.5)
Thrombocytopenia 5 (6.3) 0 4 (5.0) 9 (11.3)
Dysgeusia 6 (7.5) 2 (2.5) 0 8 (10.0)
Increased amylase 5 (6.3) 2 (2.5) 1 (1.3) 8 (10.0)
Increased lipase 5 (6.3) 0 3 (3.8) 8 (10.0)
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; GGT, gamma-
glutamyltransferase.
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With advances in genomic technologies and a 
growing knowledge of actionable mutations in targeted 
therapies, the promise of personalized medicine is growing 
[19]. In this study, an association between tumor genomic 
alteration and response was precluded by the small sample 
sizes for each genomic alteration. Additionally, genetic 
alterations in other signaling pathways may impact 
dovitinib activity. Patient-derived xenograft models have 
demonstrated the association between FGF3 and FGF19 
upregulation and response to dovitinib [20]. The presence 
of additional mutations in related signaling pathways may 
not be reflected in the dataset in this study due to the length 
of time between tumor biopsy and dovitinib treatment. 
There were few patients in which tumor biopsies were 
collected within 12 months of study start and only 13 
patients who had received no other therapy between tumor 
biopsy and dovitinib treatment. In case of the emergence of 
treatment-related genetic alterations or suppression, real-
Figure 1: Clinical benefit per tumor type cohorta. aOnly tumor types with at least 4 patients are included. bPatients for whom 
clinical benefit was non-evaluable are included under “no clinical benefit” as follows: ACC n = 1; Colorectal cancer n = 2; Gastrointestinal 
stromal tumor n = 3; HNSCC n = 3; NSCLC adenocarcinoma n = 1; ovarian n = 3; thymus n = 3. Abbreviations: ACC, adenoid cystic 
carcinoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PR, partial response; SD, stable disease.
Table 3: Summary of clinical benefit
Patients (N = 80)
Tumor response, n (%)
Complete response 0
Partial response 1 (1.3)
Stable disease (≥ 16 weeks) 10 (12.5)
Progressive disease 47 (58.8)
Non-evaluable 22 (27.5)
Clinical benefit rate, n (%) [95% CI]a 11 (13.8) [7.1–23.3]
Overall response rate, n (%) [95% CI]b 1 (1.3) [0.0–6.8]
aClinical benefit rate = complete response + partial response + stable disease for at least 16 weeks.  
bOverall response rate = complete response + partial response. Abbreviation: CI, confidence interval.
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time/fresh tumor biopsies in future trials would ensure the 
identified molecular aberrations accurately represent the 
tumor genomic background at study start.
Overall, dovitinib therapy was well tolerated in this 
heavily pretreated patient population and clinical benefit 
was observed in a subset of patients following dovitinib 
treatment. Future studies may provide additional insights 
into the role of the tumor genomic background in response 
to dovitinib therapy.
MATERIALS AND METHODS
Study design, treatment, and objectives
This was a phase 2, open-label, basket study in 
patients with solid or hematologic malignancies with 
mutations, translocations, or activations in specified 
RTK pathways whose disease had progressed on or 
following standard treatment (NCT01831726). Patients 
were treated with 500 mg/day dovitinib on a 5-days-
on/2-days-off schedule with 28-day treatment cycles 
until unacceptable toxicity, disease progression, death, or 
treatment discontinuation for any other reason. There were 
no breaks between dosing cycles. Dose interruptions or 
reductions were permitted for patients unable to tolerate 
the starting dose due to drug-related toxicities; a maximum 
of 2 dose reductions were permitted to 400 mg and 300 
mg, as needed with no dose re-escalation permitted. 
Radiological tumor assessments were performed at 
baseline, every 8 weeks (± 4 days) for the first 16 weeks 
on study, every 16 weeks (± 4 days) thereafter, and at 
the end of treatment. Safety was monitored by physical 
examinations, laboratory evaluations, and continuous 
reporting of adverse events according to the Common 
Terminology Criteria for Adverse Events v4.03.
The primary endpoint was the clinical benefit rate 
associated with dovitinib treatment per local investigator 
assessment. Clinical benefit was defined as the proportion of 
patients who achieved complete response, partial response, 
or stable disease for at least 16 weeks. Tumor response 
was assessed according to Response Evaluation Criteria In 
Solid Tumors (RECIST) v1.1 for patients with solid tumors; 
and appropriate hematologic response criteria for patients 
with hematologic tumors [12]. The key secondary endpoint 
was the overall response rate, defined as the proportion 
of patients who achieved complete or partial response. 
Additional secondary endpoints included progression-free 
survival, overall survival, duration of response, and safety 
and tolerability. The association between pathway activation 
and response to dovitinib was an exploratory endpoint.
Patient population
Adult patients (≥ 18 years) with advanced 
(surgically unresectable, recurrent, or metastatic) solid or 
hematologic malignancies with a pre-identified mutation 
and/or translocation in one or more of the following genes: 
cKIT, CSF-1R, FGFR1/2/3, FLT3, PDGFRα/β, RET, TrkA 
(NTRK1), and/or VEGFR1/2 were enrolled. Patients with 
confirmed amplification of FGFR1/2/3, FLT3, and/or 
cKIT were also included. Patients were excluded if they 
had a primary diagnosis of any of the following tumor 
types: urothelial, hepatocellular carcinoma, endometrial 
carcinoma, metastatic breast cancer, squamous non-small 
cell lung cancer, renal cell carcinoma, FLT3-mutated acute 
myeloid leukemia, and multiple myeloma.
Patients had progressive disease or relapse at 
screening, and had received at least one prior treatment for 
recurrent, metastatic, or locally advanced disease with no 
viable standard therapy options expected to result in durable 
response. Patients with solid tumors or lymphoma must 
have had measurable disease per RECIST v1.1 or Cheson 
2007 [13] criteria, respectively. Patients were excluded if 
they had received prior treatment with dovitinib or had a 
Table 4: Protocol-defined genetic aberrations based on local molecular profiling










TrkA (NTRK1) 5 (6.3)
CSF-1R 2 (2.5)
VEGFR1 0
aPatients may have alterations in more than one gene at baseline; as such, the total may exceed 100%.
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Figure 2: Genomic profile and tumor response in patients with biopsy taken within 12 months of study start. Specific 
nucleotide substitutions of PIK3CA, PIK3R1, KRAS, and TP53 are shown in Supplementary Table 2. aResponse defined as progressive 
disease despite decreased size of target lesion due to progression of existing non-target lesions, the appearance of new lesions, or progressive 
disease in target lesion at end of treatment. In the patients with sarcoma and HNSCC, progressive disease was given as the reason for 
discontinuation without imaging evidence. Abbreviations: ACC, adenoid cystic carcinoma; CNS, central nervous system; HNSCC, head 
and neck squamous cell carcinoma; NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PFS, progression-
free survival; SD, stable disease; SI, small intestine.
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known hypersensitivity to dovitinib. All patients had an 
Eastern Cooperative Oncology Group performance status 
of 0 or 1 and a life expectancy of at least 16 weeks. Patients 
with a history of pulmonary embolism, untreated deep 
venous thrombosis within 6 months prior to study start, 
impaired cardiac function, or clinically significant cardiac 
disease were excluded. Patients were also excluded if they 
had brain metastasis or a history of brain metastasis or 
leptomeningeal carcinomatosis.
Genomic profiling
Genomic profiling was not part of the screening 
process. Gene aberrations in patient tumors resulting 
in pathway activation were pre-identified in a Clinical 
Laboratory Improvement Amendments-certified 
laboratory prior to patient consent and trial enrollment. 
Archival tumor tissue or fresh tumor biopsy for central 
molecular testing was required prior to the first dose of 
dovitinib. Posthoc molecular profiling was performed 
centrally using a next-generation sequencing panel of 
>280 cancer-associated genes [14].
Statistical analysis
All efficacy endpoints were assessed in the full 
analysis set, which includes all patients who received at 
least one dose of study drug. For the primary endpoint, 
clinical benefit was evaluated in tumor cohorts containing 
at least 4 patients with a specific tumor histology using a 
novel Bayesian adaptive statistical design that allowed 
the dynamic borrowing of information across groups [15, 
16]. In each tumor cohort, clinical benefit was analyzed by 
comparing the achieved clinical benefit rate with a historical 
control rate in that tumor type. The assumed control rates 
are shown in Supplementary Table 1. A 90% probability that 
the observed response rate exceeded the historical response 
rate was required for a group to be considered a success.
Safety was assessed in all patients who received at 
least one dose of study drug and had at least one post-
baseline safety assessment.
Ethical oversight
This study was conducted in accordance with the 
Declaration of Helsinki and was performed in compliance 
with Good Clinical Practice guidelines. The protocol 
and all amendments were reviewed and approved by an 
Independent Ethics Committee and/or Institutional Review 
Board at each participating site. All patients provided 
informed consent prior to study start.
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FLT3: fms-related tyrosine kinase 3; PDGFR: platelet-
derived growth factor receptor; RECIST: Response 
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